Paper Details

  1. Home
  2. Paper Details

Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors.

Author: BulutNilufer, ErdemGokmen Umut, KapaganTanju

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study aimed to determine the prevalence of drug-drug interactions (DDI) in breast cancer patients using CDK 4/6 inhibitors, highlighting the need for increased clinical awareness among physicians regarding potential DDIs and their impact on treatment.
Paper Details　
Original Abstract of the Article :
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly changed the treatment strategy for patients with locally advanced or metastatic hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2) breast cancer. The purpose of the study was to determine the prevalence of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/10781552231218959

データ提供：米国国立医学図書館（NLM）

Polypharmacy in Metastatic Breast Cancer: A Navigating the Drug Jungle

Metastatic breast cancer, a complex and challenging disease, often requires a multifaceted approach to treatment. This study examines the prevalence of drug-drug interactions (DDIs) in patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors, a class of drugs used to treat hormone receptor-positive breast cancer.

The researchers found that DDIs were common in patients using CDK 4/6 inhibitors, highlighting the importance of careful medication management to minimize potential risks.

DDIs: A Complex Landscape of Interactions

The study underscores the complex interactions that can occur when multiple medications are used simultaneously, particularly in patients with metastatic breast cancer. Understanding these interactions is crucial for optimizing treatment outcomes and minimizing potential side effects.

Navigating the Drug Jungle: A Call for Vigilance

This research highlights the critical need for vigilant medication management in patients receiving CDK 4/6 inhibitors. By carefully monitoring potential drug interactions, healthcare professionals can help to ensure safe and effective treatment for patients with metastatic breast cancer.

Dr. Camel's Conclusion

This research delves into the complex world of drug-drug interactions in patients with metastatic breast cancer. Like a desert traveler navigating a dense forest, understanding these interactions is essential for navigating the complexities of drug therapy and ensuring the safety and efficacy of treatment.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-12-11
Further Info :

Pubmed ID

38073115

DOI: Digital Object Identifier

10.1177/10781552231218959

Related Literature

Article Analysis
・Side Effects of ribociclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.